CN119137148A - 结合白蛋白的多肽及其用途 - Google Patents

结合白蛋白的多肽及其用途 Download PDF

Info

Publication number
CN119137148A
CN119137148A CN202380037993.7A CN202380037993A CN119137148A CN 119137148 A CN119137148 A CN 119137148A CN 202380037993 A CN202380037993 A CN 202380037993A CN 119137148 A CN119137148 A CN 119137148A
Authority
CN
China
Prior art keywords
albumin
polypeptide
seq
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037993.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·霍兰德
M·马
J·C·蒂默
B·P·埃克尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinxibi Bioscience Co ltd
Original Assignee
Yinxibi Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yinxibi Bioscience Co ltd filed Critical Yinxibi Bioscience Co ltd
Publication of CN119137148A publication Critical patent/CN119137148A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380037993.7A 2022-05-05 2023-05-04 结合白蛋白的多肽及其用途 Pending CN119137148A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263338629P 2022-05-05 2022-05-05
US63/338,629 2022-05-05
US202263351362P 2022-06-11 2022-06-11
US63/351,362 2022-06-11
PCT/US2023/066580 WO2023215810A1 (en) 2022-05-05 2023-05-04 Albumin-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN119137148A true CN119137148A (zh) 2024-12-13

Family

ID=86688662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037993.7A Pending CN119137148A (zh) 2022-05-05 2023-05-04 结合白蛋白的多肽及其用途

Country Status (7)

Country Link
US (1) US20250277018A1 (enExample)
EP (1) EP4519311A1 (enExample)
JP (1) JP2025517120A (enExample)
CN (1) CN119137148A (enExample)
CA (1) CA3251817A1 (enExample)
TW (1) TW202406933A (enExample)
WO (1) WO2023215810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025144974A1 (en) * 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2025255435A2 (en) * 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
ES2393555T3 (es) 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US12479909B2 (en) * 2019-02-22 2025-11-25 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof

Also Published As

Publication number Publication date
WO2023215810A1 (en) 2023-11-09
JP2025517120A (ja) 2025-06-03
TW202406933A (zh) 2024-02-16
US20250277018A1 (en) 2025-09-04
EP4519311A1 (en) 2025-03-12
CA3251817A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CN115003333B (zh) Pvrig结合蛋白及其医药用途
KR102845959B1 (ko) Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
JP6817211B2 (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
AU2014292924B2 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US11021694B2 (en) SIRP-α immunoglobulin fusion proteins
JP7554781B2 (ja) 抗ｃｅａｃａｍ５モノクローナル抗体およびその調製方法およびその使用
JP2019534845A (ja) マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
EP4393950A1 (en) Fap/cd40 binding molecule and medicinal use thereof
KR20170138494A (ko) 항-ｔｙｒ０３ 항체 및 이의 용도
EP4403574A1 (en) Protein specifically binding to pd-1 and pharmaceutical use thereof
KR20210076918A (ko) 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
US20250277018A1 (en) Albumin-Binding Polypeptides and Uses Thereof
CN115776990A (zh) 犬类pd-1结合多肽及其用途
JP2025515304A (ja) Ｓｉｇｌｅｃ－８結合タンパク質及びその使用方法
US20220267458A1 (en) Miniaturized antibody of anti-glucocorticoid-induced tumor necrosis factor receptor (gitr), and polymer and use thereof
JP2021514654A (ja) Ｃｓｆ１ｒ結合剤
JP2023545968A (ja) 低減された凝集能及び低減された疎水性を有する改善された抗ｏｘＭＩＦ抗体
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
TW202246313A (zh) 與Ｆｃ受體結合改變的Ｆｃ突變體
US20250353911A1 (en) FcRn-Binding Polypeptides and Uses Thereof
KR20260049221A (ko) 변형된 e형 다중특이성 항체
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
JP2025528101A (ja) 多重特異性ポリペプチド複合体
CN121941712A (zh) IgE结合蛋白及其用途
CN121335921A (zh) 免疫球蛋白Fc区结合蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination